Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo maintains a Buy rating on ENDRA Life Sciences (NASDAQ:NDRA) but lowers the price target from $10 to $8.
June 07, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on ENDRA Life Sciences but lowers the price target from $10 to $8.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations for short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100